- Home
- COYA vs ENTX Comparison
COYA vs ENTX Comparison
Compare COYA & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COYA
- ENTX
- Stock Information
- Founded
- COYA 2020
- ENTX 2010
- Country
- COYA United States
- ENTX Israel
- Employees
- COYA N/A
- ENTX N/A
- Industry
- COYA Biotechnology: Pharmaceutical Preparations
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- COYA Health Care
- ENTX Health Care
- Exchange
- COYA Nasdaq
- ENTX Nasdaq
- Market Cap
- COYA 103.2M
- ENTX 104.0M
- IPO Year
- COYA 2022
- ENTX 2018
- Fundamental
- Price
- COYA $5.93
- ENTX $2.03
- Analyst Decision
- COYA Strong Buy
- ENTX Strong Buy
- Analyst Count
- COYA 4
- ENTX 1
- Target Price
- COYA $17.00
- ENTX $10.00
- AVG Volume (30 Days)
- COYA 66.8K
- ENTX 45.1K
- Earning Date
- COYA 05-13-2025
- ENTX 05-09-2025
- Dividend Yield
- COYA N/A
- ENTX N/A
- EPS Growth
- COYA N/A
- ENTX N/A
- EPS
- COYA N/A
- ENTX N/A
- Revenue
- COYA $3,685,107.00
- ENTX $223,000.00
- Revenue This Year
- COYA $94.45
- ENTX N/A
- Revenue Next Year
- COYA N/A
- ENTX N/A
- P/E Ratio
- COYA N/A
- ENTX N/A
- Revenue Growth
- COYA N/A
- ENTX N/A
- 52 Week Low
- COYA $4.65
- ENTX $1.41
- 52 Week High
- COYA $10.24
- ENTX $2.79
- Technical
- Relative Strength Index (RSI)
- COYA 48.29
- ENTX 48.27
- Support Level
- COYA $5.63
- ENTX $1.84
- Resistance Level
- COYA $6.53
- ENTX $2.24
- Average True Range (ATR)
- COYA 0.46
- ENTX 0.15
- MACD
- COYA -0.03
- ENTX -0.04
- Stochastic Oscillator
- COYA 29.70
- ENTX 31.32
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.